Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122466 · ClinicalTrials.gov registry record
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
A clinical trial of Metastatic Pancreatic Cancer, sponsored by Northwell Health.
- Active
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT07122466 is a study of Metastatic Pancreatic Cancer that is active but no longer recruiting, run by Northwell Health. The registered enrollment target is 24 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07122466, a study of Metastatic Pancreatic Cancer, is active but no longer recruiting, sponsored by Northwell Health.
- ACTIVE NOT RECRUITING
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)
Study Locations (1)
New York
- Zuckerberg Cancer Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2025-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07122466
The ClinicalTrials.gov registry entry for NCT07122466 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) is the first listed.
NCT07122466 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07122466 about?
NCT07122466 is a clinical study titled "Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy". This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the st...
What is the current status of trial NCT07122466?
This trial is currently active not recruiting. The enrollment target is 24 participants. The study started on 2023-05-22. Estimated completion is 2025-09.
What conditions does trial NCT07122466 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT07122466?
The interventions under investigation include: Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07122466?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122466 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 1
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.